Can I Take Vitamin B12 with Jardiance (Empagliflozin)?

The Short Answer: Jardiance and Vitamin B12 Are Safe Together

Empagliflozin does not affect how the body absorbs, distributes, metabolizes, or excretes vitamin B12. No pharmacokinetic drug-nutrient interaction has been identified in the peer-reviewed literature or in the FDA-approved prescribing information for Jardiance. You do not need to separate doses or take any special precautions specifically because of empagliflozin.

The clinical picture is rarely that simple for patients with type 2 diabetes. Most people prescribed Jardiance are also taking metformin, and metformin is one of the few oral drugs with a well-documented, mechanism-based ability to lower serum B12 over time. The distinction matters: the risk comes from your full medication regimen, not from Jardiance alone.

Why This Question Comes Up So Often

Patients and clinicians ask about B12 and Jardiance because diabetes itself is associated with B12 insufficiency through multiple routes. Poor diet, gastrointestinal autonomic dysfunction, and proton-pump inhibitor co-use all reduce B12 absorption independently of any drug [1]. Add metformin into the mix and the risk rises further. Because Jardiance is frequently prescribed alongside metformin, the concern gets attached to Jardiance by association, not by direct mechanism.

What Empagliflozin Actually Does

Empagliflozin blocks sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, preventing reabsorption of filtered glucose and causing roughly 70 to 90 grams of glucose to be excreted in urine each day [2]. This mechanism has no contact point with B12 metabolism, intrinsic factor production, or the ileal transport proteins responsible for B12 absorption.

How Metformin Depletes Vitamin B12: The Real Mechanism

Metformin's effect on B12 is pharmacodynamic, not metabolic. It interferes with the calcium-dependent membrane action of cubilin, the ileal receptor complex that binds the intrinsic factor-B12 complex and allows its uptake [3]. The result is reduced ileal absorption of B12 that is dose-dependent and accumulates over years of use.

The UKPDS follow-up data and prospective cohort work published in the BMJ confirm that metformin users show progressively declining serum B12. One analysis of 155 patients treated with metformin for a median of 13 years found a 19% prevalence of B12 deficiency compared with 5% in matched controls [4].

Dose and Duration Matter

Higher metformin doses and longer treatment durations predict lower B12 levels. Patients taking 2,000 mg per day or more are at approximately twice the risk compared with those on 1,000 mg or less [3]. Because most patients on empagliflozin-plus-metformin combinations (such as Synjardy, the fixed-dose empagliflozin/metformin tablet) take metformin at doses of 1,000 to 2,000 mg daily, B12 depletion is a genuine and underappreciated concern in this population.

The Neuropathy Diagnostic Problem

Peripheral neuropathy from B12 deficiency and diabetic peripheral neuropathy share nearly identical symptoms: numbness, tingling, and burning discomfort, typically starting in the feet. The American Diabetes Association (ADA) 2024 Standards of Care state directly: "Long-term metformin use is associated with biochemical vitamin B12 deficiency... Periodic measurement of vitamin B12 levels should be considered in metformin-treated patients, especially in those with peripheral neuropathy or anemia" [5]. Unrecognized B12 deficiency in a patient whose symptoms are attributed entirely to diabetic neuropathy is a meaningful missed diagnosis.

Does Empagliflozin Affect B12 Levels Independently?

No published randomized controlled trial or cohort study has demonstrated that empagliflozin independently alters serum B12 concentrations. The EMPA-REG OUTCOME trial (N=7,020 patients with type 2 diabetes and established cardiovascular disease) reported a 14% relative reduction in cardiovascular death with empagliflozin 10 mg versus placebo over a median 3.1 years, but B12 levels were not a pre-specified outcome [6]. No signal of B12 depletion appeared in the safety data.

The EMPEROR-Reduced trial (N=3,730 patients with heart failure with reduced ejection fraction) similarly found no metabolic micronutrient depletion linked to empagliflozin in its safety reporting [7]. The mechanism explains why: SGLT2 inhibition is confined to the renal tubule and has no plausible route to intestinal B12 transport.

Osmotic Diuresis and Micronutrient Losses: A Theoretical Concern

Some clinicians ask whether Jardiance-induced glucosuria and mild osmotic diuresis might flush water-soluble vitamins including B12 through the kidneys. B12 is not freely filtered at the glomerulus to any meaningful degree because it circulates bound to haptocorrin and transcobalamin proteins, not as free cobalamin [8]. Renal losses of protein-bound B12 are negligible in patients with intact tubular function. This theoretical concern does not appear to translate into measurable B12 depletion in clinical practice.

Who Should Pay Closest Attention to B12 Status on Jardiance?

Not every patient on Jardiance needs aggressive B12 monitoring. Risk stratification helps focus clinical effort where it matters most.

Higher-Risk Patients

The following patient profiles deserve a baseline serum B12 and annual monitoring:

• Patients taking metformin concurrently, especially at doses above 1,500 mg/day or for more than 3 years
• Adults over age 65, because gastric atrophy reduces intrinsic factor production with age and prevalence of B12 deficiency in adults over 65 reaches 6 to 15% depending on the cohort [1]
• Patients following vegan or strict vegetarian diets, since dietary B12 comes almost exclusively from animal products
• Patients on proton pump inhibitors (PPIs) long-term, given that gastric acid is required to cleave food-bound B12 from protein [9]
• Patients with existing peripheral neuropathy where B12-deficiency neuropathy could worsen or be confused with diabetic neuropathy

Lower-Risk Patients

A patient taking Jardiance as monotherapy or combined only with a sulfonylurea or DPP-4 inhibitor, eating an omnivorous diet, and under age 50 with no GI complaints has minimal reason to expect B12 depletion attributable to their drug regimen. A single baseline check is still reasonable, but intensive follow-up is not required based on current evidence.

Recommended Vitamin B12 Supplementation: Forms, Doses, and Practical Guidance

When supplementation is indicated, the form and dose of B12 influence how well deficiency is corrected.

Oral vs. Intramuscular B12

For most patients, high-dose oral B12 (1,000 mcg/day of cyanocobalamin or methylcobalamin) corrects deficiency as effectively as intramuscular injections when the cause is reduced intrinsic-factor-dependent absorption, because roughly 1 to 2% of a very large oral dose is absorbed by passive diffusion independent of intrinsic factor [10]. A Cochrane review of oral versus intramuscular B12 for deficiency found that 2,000 mcg oral cyanocobalamin daily was as effective as intramuscular administration in normalizing serum B12 after 90 days [10].

Intramuscular hydroxocobalamin or cyanocobalamin (1,000 mcg every 1 to 3 months) is reserved for patients with severe neurological symptoms, confirmed pernicious anemia, or malabsorption syndromes where even passive diffusion is impaired.

Methylcobalamin vs. Cyanocobalamin

Both forms are effective for correcting deficiency in most people. Methylcobalamin is the active coenzyme form and requires no hepatic conversion, which makes it theoretically preferable for patients with liver disease or genetic polymorphisms affecting cobalamin metabolism. Cyanocobalamin is more stable, less expensive, and backed by the longest clinical trial record. For a patient on Jardiance without special circumstances, either form at 500 to 1,000 mcg/day is appropriate.

Timing Relative to Jardiance

Jardiance is typically taken in the morning with or without food. B12 supplements can be taken at the same time. There is no interaction, no absorption competition, and no need to separate the doses.

Food Sources Worth Knowing

Dietary B12 content of common foods: beef liver contains approximately 70 mcg per 3-ounce serving, clams provide roughly 84 mcg per 3 ounces, salmon delivers about 4.9 mcg per 3 ounces, and one large egg contains approximately 0.6 mcg [11]. For patients eating these foods regularly in adequate amounts, supplementation may be unnecessary unless metformin or another absorption-disrupting factor is present.

Monitoring B12 Status: What Tests to Order and When

Serum B12 alone can miss early deficiency because it remains in the normal range while tissue stores deplete. A more sensitive approach combines serum B12 with methylmalonic acid (MMA) and homocysteine measurements.

Interpreting the Numbers

Serum B12 below 200 pg/mL (148 pmol/L) is typically considered deficient. Values between 200 and 300 pg/mL are in a gray zone where MMA and homocysteine help. Elevated MMA (above 271 nmol/L) is the most specific functional marker of intracellular B12 insufficiency, reflecting impaired activity of methylmalonyl-CoA mutase [12]. Elevated total homocysteine (above 15 micromol/L) suggests B12 or folate insufficiency but is less specific.

The ADA recommends periodic B12 testing for metformin-treated patients without specifying a precise interval. In practice, annual testing is reasonable for patients on metformin doses above 1,000 mg/day, with more frequent testing if neuropathy symptoms develop or dietary intake is limited [5].

When to Escalate

If serum B12 falls below 200 pg/mL in a symptomatic patient, treatment should begin promptly. Neurological damage from B12 deficiency may be irreversible if deficiency is prolonged, a point reinforced by a 2019 review in JAMA Internal Medicine noting that subacute combined degeneration of the spinal cord, a severe neurological complication, can develop within months of severe deficiency onset [12].

What the Clinical Guidelines Say

The ADA 2024 Standards of Care in Diabetes, published in Diabetes Care, recommend: "Patients on metformin should be periodically assessed for B12 deficiency as metformin use is associated with a reduction in B12 absorption" [5]. This guidance applies directly to patients on Jardiance plus metformin.

The Endocrine Society does not currently list a B12-specific interaction with SGLT2 inhibitors in its clinical practice guidelines for type 2 diabetes pharmacotherapy [13].

The Natural Medicines database rates the interaction between empagliflozin and vitamin B12 as "no known interaction," distinguishing it from the metformin-B12 interaction, which is rated "moderate" based on mechanism and clinical evidence [14].

No major cardiology guideline, including the 2022 AHA/ACC/HFSA Heart Failure Guideline that recommends SGLT2 inhibitors for heart failure with reduced ejection fraction, identifies B12 monitoring as a class-specific concern for SGLT2 inhibitor use [15].

Practical Summary for Patients and Clinicians

Jardiance does not deplete vitamin B12 through any known mechanism. Taking a B12 supplement while on Jardiance is safe, requires no dose separation, and carries no pharmacokinetic risk.

The clinical action items center on the broader medication context. Any patient on Jardiance who is also taking metformin should have a serum B12 level checked at baseline and at least annually. Patients with peripheral neuropathy symptoms should have MMA measured alongside serum B12 to rule out functional deficiency before attributing symptoms entirely to diabetic neuropathy.

For confirmed or suspected deficiency in a metformin co-user, oral cyanocobalamin or methylcobalamin at 1,000 mcg/day is a first-line correction approach backed by Cochrane-level evidence [10]. Recheck serum B12 after 3 months to confirm response.

Patients not on metformin and eating an omnivorous diet have low baseline risk of B12 depletion from their Jardiance prescription. A one-time baseline serum B12 check remains reasonable given the high background prevalence of subclinical deficiency in the general adult population, which the NIH Office of Dietary Supplements estimates at 6% in adults aged 20 to 59 and rises to 20% in those over 60 [11].